Truxima Indications/Uses

Non-Hodgkin's Lymphoma: Truxima is indicated for the treatment of: patients with relapsed or chemoresistant low-grade or follicular, CD20-positive, B-cell non-Hodgkin's lymphoma; previously untreated patients with stage III-IV follicular lymphoma in combination with chemotherapy; patients with follicular lymphoma as maintenance treatment, after response to induction therapy; patients with CD20-positive diffuse large B-cell non-Hodgkin's lymphoma in combination with CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) chemotherapy.
Truxima in combination with chemotherapy is indicated for the treatment of pediatric patients (aged ≥ 6 months to < 18 years old) with previously untreated advanced stage CD20 positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL)/Burkitt leukaemia (mature B-cell acute leukaemia) (BAL) or Burkitt-like lymphoma (BLL).
Chronic Lymphocytic Leukaemia: Truxima in combination with chemotherapy is indicated for the treatment of patients with previously untreated and relapsed/refractory chronic lymphocytic leukaemia (CLL).
Rheumatoid Arthritis: Truxima in combination with methotrexate is indicated in adult patients for: the treatment of moderate to severe, active rheumatoid arthritis when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate; treatment of moderate to severe, active rheumatoid arthritis in patients with an inadequate response or intolerance to one or more tumour necrosis factor (TNF) inhibitor therapies.
Truxima has been shown to reduce the rate of progression of joint damage as measured by x-ray, to improve physical function and to induce major clinical response, when given in combination with methotrexate.
Adult and Pediatric Patients with Granulomatosis with Polyangiitis (Wegener's) (GPA) and Microscopic Polyangiitis (MPA): Truxima in combination with glucocorticoids is indicated for the treatment of adult patients with severe active granulomatosis with polyangiitis (GPA, also known as Wegener's Granulomatosis) and microscopic polyangiitis (MPA) (see PHARMACOLOGY: Pharmacodynamics: Clinical/Efficacy Studies under Actions).
Truxima, in combination with glucocorticoids, is indicated for the induction of remission in pediatric patients (aged ≥ 2 to < 18 years old) with severe, active GPA (Wegener's) and MPA.
Pemphigus Vulgaris: Truxima is indicated for the treatment of patients with moderate to severe pemphigus vulgaris (PV).